# A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy

> **NCT07176702** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Metastatic PDAC
- HER2-positive Status

## Interventions

- **DRUG:** HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy

## Key facts

- **NCT ID:** NCT07176702
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2027-03-05
- **Final completion:** 2027-09-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07176702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07176702, "A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07176702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*